ArticleBMC pharmacology & toxicology2025
Selinexor, a selective inhibitor of nuclear export, shows anti-proliferative and anti-migratory effects on male germ cells in vitro.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Doxorubicin and 4-Hydroperoxycyclophosphamide Alter Mitochondrial Dynamics and miR-34 Expression in Spermatogonia and Spermatocytes In Vitro.Basic & clinical pharmacology & toxicology · 2026Article
- Synthesis and Characterization of Juglone-Derived cu (II), Mn (II) and Zn (II) Complexes and Investigation of Their Cytotoxic Activities Against Lung and Colon Cancer Cells in Vitro and in Silico.Journal of applied toxicology : JAT · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundSelinexor (SLX), a selective inhibitor of nuclear export (SINE), has been shown to interfere with nuclear export mechanisms and to exert antitumor effects in a variety of cancer cell types. It is known to regulate multiple fundamental cellular processes, including the DNA damage response, cell proliferation, and stress signaling pathways. Nevertheless, its potential effects on reproductive cells remain inadequately characterized. The present study was aimed to investigate the cytotoxic, apoptotic, anti-proliferative and anti-migratory effects of SLX on GC1 (spermatogonia) and GC2 (spermatid) cell lines, alongside its influence on DNA damage and oxidative stress.
methodsCytotoxicity was assessed using the MTT assay. Cell proliferation capacity was evaluated via colony formation assay, while cell migration was analyzed using in vitro wound healing model. Apoptosis, oxidative stress, and DNA damage were investigated using immunocytochemical analyses of Cas-3, Bax, iNOS, ATM, and BRCA1 proteins. Additionally, Annexin V-FITC/PI staining was performed to detect the apoptotic cell population by flow cytometry.
resultsSLX treatment led to concentration- and time dependent cytotoxicity and colony formation assay revealed a marked reduction in proliferative capacity, in both cell lines. Wound healing analyses demonstrated that SLX effectively suppressed cell migration. Flow cytometry analysis showed that the live cell population decreased, whereas the late apoptotic cell population increased. Additionally, it was observed that Cas-3 and Bax immunoreactivities increased in the SLX groups compared to the control groups. Moreover, a significant increase in the immunoreactivity of ATM, BRCA1 and iNOS proteins, which are key indicators of DNA damage and oxidative stress, was observed.
conclusionThe data suggest that SLX may decrease cell viability, induce apoptosis, inhibit cell migration and increase DNA damage and cellular stress in male germ cells. Given these effects, SLX should be carefully examined for its potential reproductive toxicity. Further studies are warranted to explore its long-term impact on male fertility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.